Apologies @w_i_z_z_a I confused Dementia with Parkinsons.....maybe I have early on-set dementia
So yes potentially Neuren's NNZ-2591 MOA could be effective albeit I'm comfortable that their experience with Retts & Trofinetide gives them a massive head start with the 4 other rare diseases (there's not many other co. exploring treatments for those 4) in lieu of putting time, energy and significant $ into a field that has myriad no. of companies developing drugs for Parkinsons.
Ann: Investor Presentation, 14 March 2023, page-92
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.54 |
Change
0.680(3.42%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $5.133M | 252.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24 | $20.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.55 | 1109 | 5 |
View Market Depth
| Last trade - 15.30pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |